Loading
Obesity / Glucagon-like Peptide-1 Receptor Agonists / Glp-1 Receptor Agonists · Journal article
Pulmonology · August 25, 2026
Early or partial results. Treat as a signal, not a conclusion.
This cross-sectional survey documents current practice patterns in the use of GLP-1 receptor agonists for obesity and obstructive sleep apnoea across European sleep centres. The study identifies substantial variability in diagnostic timing, positive airway pressure management, and follow-up strategies, but provides no comparative efficacy data or patient outcomes.
Multinational cross-sectional survey. Sleep centres participating in the ESADA network across 14 European countries; represents current clinical practice in European sleep medicine.. Intervention: Current clinical practice patterns regarding GLP-1 receptor agonist use in OSA management. 24 centres in 14 European countries.
42% of centres reported that GLP-1RA therapy could be initiated by sleep physicians within the sleep clinic 92% of clinicians continued to recommend diagnostic sleep studies in symptomatic patients recently started on GLP-1RAs; 81% in asymptomatic patients 61% of centres considered a weight loss threshold >10% clinically meaningful for OSA reassessment
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This survey reveals substantial heterogeneity in European clinical practice regarding GLP-1RA use in sleep medicine, including diagnostic timing and positive airway pressure management strategy. Clinicians should recognize the lack of harmonised guidance and consider the urgent need for multidisciplinary coordination when integrating GLP-1RAs into their OSA management protocols.
A descriptive survey of clinical practice patterns across European sleep centres documenting current use of GLP-1RAs in OSA; reports frequencies of practices but no comparative outcomes, efficacy data, or causal inference.
As stated by the source record.
Quoted from the source exactly as published.
This survey reveals substantial heterogeneity in European clinical practice regarding GLP-1RA use in sleep medicine, including diagnostic timing and positive airway pressure management strategy. Clinicians should recognize the lack of harmonised guidance and consider the urgent need for multidisciplinary coordination when integrating GLP-1RAs into their OSA management protocols.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 agonists have demonstrated weight loss benefits and reductions in obstructive sleep apnoea (OSA) severity. Following recent regulatory approval of tirzepatide for OSA with obesity, their integration into sleep medicine is accelerating. However, real-world clinical practice remains undefined.Methods. The European Sleep Apnoea Database (ESADA) network conducted a multinational online survey across 24 centres in 14 European countries to evaluate current practice patterns regarding GLP-1RA use in patients with obesity and suspected or established OSA.Results. Forty-two percent of centres reported that GLP-1RA therapy could be initiated by sleep physicians within the sleep clinic. Indications were consistent, primarily targeting moderate-to-severe obesity with metabolic comorbidities. Most clinicians continued to recommend diagnostic sleep studies in symptomatic (92%) and asymptomatic (81%) patients recently started on GLP-1RAs. A weight loss threshold > 10% was considered clinically meaningful for OSA reassessment by 61% of centres. Despite anticipated reductions in OSA severity, proactive positive airway pressure (PAP) re-titration or withdrawal was uncommon (14%). Monitoring focused on weight trajectory, symptoms, and PAP telemonitoring. Structured interdisciplinary pathways were largely absent.Conclusions. GLP-1RAs are increasingly incorporated into European sleep practice; however, substantial variability exists in diagnostic timing, PAP management, and follow-up strategies. Harmonised guidance and coordinated multidisciplinary care are urgently needed.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.